Principal shareholder of Genovis reduced his holdings

The Genovis Board of Directors learned today that a shareholding has changed owners. The seller is Mikael Lönn, the company’s largest shareholder and a director for Genovis. The shareholding of 2,500,000 shares represents about 20 percent of Lönn’s holdings. After the sale, Lönn holds 9,990,653 shares in Genovis, which represents approximately 16 percent of the company's shares and votes. Consequently, even after the transaction Lönn is still the company’s largest shareholder. 

In a comment to the company Lönn says:

“I have followed Genovis since 2011 and am pleased to say that the performance of the company has been outstanding in recent times. I expect that this favorable trend will continue and I plan to continue to my commitment to ownership, even though I am now selling a portion of my holdings for personal reasons.”

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com


ABOUT GENOVIS

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.


About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links